Digest Network Come funziona
Network
/
Società
Ly
Non verificato

Lysoway Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteSanità

5 comunicati stampa

Guarda tutti i comunicati
01/06/2026
Volontariato/Solidarietà/Non profit
Medicina - Varie
Associazioni/Professionisti
Biotecnologia
Sanità
Farmaceutica
Vetrine/Shopping
Salute
Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TMEM175 Agonists for Parkinson’s Disease
Fonte
Lysoway Therapeutics, Inc.
Emittente
Business Wire
1.00
0
11/05/2026
Industria
Biotecnologia
Sanità
Salute
Farmaceutica
Scienza
Medicina - Varie
Lysoway Therapeutics Announces Phase I Dosing of LW-1017, the First TRPML1 Agonist to Enter Clinical Development
Fonte
Lysoway Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/01/2026
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Lysoway Therapeutics Announces Phase I Readiness of Brain-Penetrant TRPML1 Agonist LW-1017 and Nomination of a TMEM175 Development Candidate
Fonte
Lysoway Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/01/2026
Industria
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Lysoway Therapeutics Announces Phase I Readiness of Brain-Penetrant TRPML1 Agonist LW-1017 and Nomination of a TMEM175 Development Candidate
Fonte
Lysoway Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/08/2025
Sanità
Scienza
Associazioni/Professionisti
Farmaceutica
Vetrine/Shopping
Medicina - Varie
Biotecnologia
Salute
Volontariato/Solidarietà/Non profit
Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson’s Disease
Fonte
Lysoway Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0